Celltrion Pharm Launches Dual Antihypertensive Combination Drug "Ildipin Tablets"

Superior Blood Pressure Lowering Effect Compared to Monotherapy
with Once-Daily, Single-Tablet Dosing

Celltrion Pharm announced on January 2 that it has launched 'Ildipin Tablets' (active ingredients: azilsartan medoxomil and amlodipine), a dual antihypertensive combination drug, in the domestic market.

Ildipin Tablets is an improved combination drug that combines 'azilsartan medoxomil', an angiotensin II receptor blocker (ARB) known for its 24-hour stable blood pressure lowering effect, with 'amlodipine', a representative calcium channel blocker (CCB). By combining these two agents with different mechanisms of action, the drug enables stable blood pressure control.

Ildipin Tablets, a dual antihypertensive combination drug by Celltrion Pharm. Celltrion Pharm

The main target patients for Ildipin Tablets are those with essential hypertension whose blood pressure is not adequately controlled by monotherapy with either azilsartan medoxomil or amlodipine, or patients who are already taking both agents separately and require improved medication convenience. In fact, a clinical study conducted at 10 institutions in Korea and abroad, titled 'Evaluation of the antihypertensive effect and safety of combination therapy in patients with mild to moderate essential hypertension not controlled by monotherapy', confirmed that the combination therapy lowered systolic blood pressure more effectively than monotherapy.

Ildipin Tablets is designed for once-daily, single-tablet dosing, which enhances convenience and medication adherence, and it is characterized by its ability to provide stable blood pressure control without 24-hour blood pressure variability. In addition, compared to some other ARB drugs, it has also shown results in renal protection and reduction of proteinuria, making it suitable for a wide range of patients, including those with hypertension accompanied by type 2 diabetes.

Ildipin Tablets received product approval from the Ministry of Food and Drug Safety in October last year and has been covered by the national health insurance since January 1, with prescriptions now available. Two dosages based on azilsartan medoxomil/amlodipine-40/5mg and 40/10mg-have been launched first, with insurance prices set at 654 KRW and 725 KRW, respectively, according to the Ministry of Health and Welfare's drug price notification. In February, the company plans to introduce additional 80/5mg and 80/10mg products, further expanding tailored prescription options according to patient status.

The importance of combination therapy in the domestic hypertension treatment landscape continues to grow. According to pharmaceutical market research firm UBIST, the number of patients taking dual combination drugs of ARB and CCB increases by an average of 4.6% annually, and the related market size is approximately 840 billion KRW. By launching Ildipin Tablets following the release of Edarbi and Edarbyclo, Celltrion Pharm aims to strengthen its cardiovascular treatment portfolio and provide patients with a wider range of therapeutic options.

A Celltrion Pharm representative stated, "Ildipin Tablets is a product that not only offers superior blood pressure lowering effects compared to monotherapy but also improves medication adherence with once-daily, single-tablet dosing," adding, "We expect it will help expand treatment options for patients with hypertension."